Aprea Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Aprea Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $14.60 million for the year ending 2025.

  • Aprea Therapeutics, Inc. showed a decrease of -36.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Aprea Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
  • XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 8 years of available data (2018 to 2025), Aprea Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 77.8%.
  • Historical annual values: Fiscal year 2025: $14.60 million | Fiscal year 2024: $22.85 million | Fiscal year 2023: $21.61 million | Fiscal year 2022: $28.79 million | Fiscal year 2021: $53.08 million | Fiscal year 2020: $89.02 million | Fiscal year 2019: $130.09 million | Fiscal year 2018: $65.68 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: